Karyopharm Therapeutics
KPTI
KPTI
157 hedge funds and large institutions have $949M invested in Karyopharm Therapeutics in 2020 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 55 increasing their positions, 53 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
157
Holders Change
+2
Holders Change %
+1.29%
% of All Funds
3.18%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
29
Increased
55
Reduced
53
Closed
27
Calls
$7.81M
Puts
$4.85M
Net Calls
+$2.96M
Net Calls Change
-$5.5M
Top Buyers
| 1 |
Two Sigma Investments
New York
|
+$15.4M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$13.3M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$12.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11.5M |
| 5 |
BlackRock
New York
|
+$11.4M |
Top Sellers
| 1 |
CCM
Consonance Capital Management
New York
|
-$123M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$25.3M |
| 3 |
Goldman Sachs
New York
|
-$16.6M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$14.6M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$8.77M |
